Exchange: NYSEArca·Updated 07:52 PM EDT

XBI News

News
all
press releases
Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027
In studies on non-human primates, EDIT-401 reduced bad cholesterol and other harmful blood fats by around 90%.
Stocktwits
Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027
In studies on non-human primates, EDIT-401 reduced bad cholesterol and other harmful blood fats by around 90%.
Stocktwits
More News
Why Is ARGX Stock Plunging Today?
Argenx said it would discontinue its Phase 3 Unity study of Efgartigimod SC in adults with moderate-to-severe Sjögren’s disease, an autoimmune condition.
Stocktwits
IBRX Stock Under Pressure: Retail Sees 'Ridiculously Cheap' Bargain As Founder Touts Sister Firm NantIQ's Aetna Work
The initiative aligns with Soon-Shiong’s ‘Immunotherapy 2.0’ vision, combining immune treatments, diagnostics and monitoring to help prevent cancer recurrence.
Stocktwits
CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision
Craig McDonald said on Wednesday that in patients in the HOPE-3 trial with weakened hearts, Deramiocel treatment produced “essentially complete stabilization” over a year.
Stocktwits
Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity
The FDA awarded the voucher after approving Genglycos, a glycogen storage disease type Ia treatment, in August.
Stocktwits
CRBU Stock Crashes 35% Premarket — RBC Slashes Target By 90% After Caribou Scraps CAR-T Programs
Caribou said it would stop work on both of its clinical-stage CAR-T programs and consider strategic options including a merger, acquisition, or sale of assets.
Stocktwits
AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’
ArriVent BioPharma’s experimental lung cancer treatment failed to meet its primary endpoint in a Phase 3 trial.
Stocktwits
PacBio Deepens AI Drug-Discovery Push With TychoBio Deal — PACB Stock Takes A Breather After 103% Rally
PacBio will generate full-length RNA data from more than 10,000 samples, which TychoBio will use to train AI models to design treatments for rare diseases
Stocktwits
NVAX, EBS, ARCT, MRNA Rally After Russia Plague Lab Worker's Death: Retail Traders Eye 'Contract Awards'
No plague case has been confirmed, and no government orders have been announced, but outbreak-linked stocks jumped anyway.
Stocktwits
Eli Lilly’s Push Beyond Weight Loss Gets Another Boost – FDA Grants Cancer Drug Orphan Drug Status
The designation, given to therapies being developed for rare diseases, enables Lilly to receive potential incentives, including clinical trial tax credits, exemption from certain FDA fees, and exclusivity.
Stocktwits

Advertisement|Remove ads.